To calculate new biomarkers and its efficacy of the progresion for non-alcoholic fatty liver disease patients.

To calculate new biomarkers and its efficacy of the progresion for non-alcoholic fatty liver disease patients. - To calculate new biomarkers and its efficacy of the progresion for non-alcoholic fatty liver disease patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014550

Enrollment

600

Registered

2014-07-15

Start date

2014-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease (NAFLD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with diagnosed NAFLD

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Staging of fibrosis and inflammatory with NAFLD liver.	—

Countries

Japan

Contacts

Public ContactMichiharu Komatsu

Shinshu Univercity of Medicine Gastoenterology

komichi@shinshu-u.ac.jp0263-35-4600

Outcome results